Marin Richeson

Over the past several weeks, I’ve published a series of posts that focus on segments of an article published by McKinsey & Company called “How pharma can win in a digital world.” (See the bottom of this post for links to the previous posts.) At the end of the McKinsey article, the authors describe “three […]

A couple of weeks ago, I took an in-depth look at the second of three critical themes for success in the digital age, as identified by McKinsey & Company through interviews with 20 pharma executives: It is time to reimagine them as solutions companies, not asset companies. In today’s post, I’d like to take a […]

The other day, I was on a business development call in which the Appian platform was discussed. Appian happens to be a “Leader” in Gartner’s 2015 Magic Quadrant for Intelligent Business Process Management Suites. Not too shabby. The presenter talked about Perficient’s successes with Appian in financial services and healthcare, but when I heard him […]

In a recent post, I took an in-depth look at the first of three critical themes for success in the digital age, as identified by McKinsey & Company through interviews with 20 pharma executives: 

In a recent blog post, I mentioned the three critical themes for success in the digital age, as identified by McKinsey & Company through interviews with 20 pharma executives: 

I don’t often see FDA Warning Letters issued to Institutional Review Boards (IRBs), so, when I came across this one, I thought it was worth sharing with you. This particular IRB was found to be in violation of 21 CFR Part 56.115(a)(2), related to meeting minutes, and 21 CFR Part 56.115(a)(5), related to a complete […]

I enjoy reading FDA Warning Letters. They’re insightful and often entertaining. Sometimes, though, they’re kind of unbelievable. And, sometimes, they’re downright nauseating. Take, for example, this letter issued on February 19, 2016 to a principal investigator (PI) based in New York. FDA inspectors found him to be in violation of 21 CFR Part 312.62(b), related […]

Last week, I wrote a post about an article published by McKinsey & Company in which they interviewed 20 pharma executives about how they’re handling digital transformation. The article was jam-packed with great information, so I wanted to highlight a few more points for you. 

  In a recent article, McKinsey & Company shared the results of 20 interviews with leading executives in pharma about the “digital revolution.” Through the interviews, McKinsey sought to learn how pharma companies plan to stay ahead of inherent changes in the age of digital. 

  In my tenure here at Perficient, I’ve contributed to a number of guides for the life sciences industry. Each one has been informative and useful, but I can’t remember ever being as excited about any of them as I am about the newest one: Life Sciences is Going Digital. 

  On January 8, 2016, the FDA issued a warning letter that caught my attention. I can’t remember why I initially opened it; maybe because the company’s name had “pharm” in it, as opposed to “seafood” (which seems to be there a lot!). Once inside the letter, I found this in the opening paragraph: “This […]

  On January 14, 2016, Perficient hosted a webinar titled Leveraging Siebel CTMS for Risk-Based Monitoring. We received some good questions during the webinar and figured we’d share them (and the answers) with you.